| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg, inclusive, on 2 consecutive visits (weeks 2 and 4 of run‐in) with </= 10mm Hg difference between 2 visits; 4‐week double‐blind treatment |
| Participants |
Benazepril 5 mg: n=38(23 males,15 females); mean age=51.1 years; baseline sitting SBP=152.7(15.2) mm Hg, DBP=101.2(5.3) mm Hg;
Benazepril 10 mg: n=34(23 males,11 females); mean age=51.9 years; baseline sitting SBP=153.1(13.7) mm Hg, DBP=101.8(5.7) mm Hg;
Benazepril 20 mg: n=36(23 males,13 females); mean age=50.4 years; baseline sitting SBP=151.9(15.7) mm Hg, DBP=101.7(4.7) mm Hg;
Benazepril 40 mg: n=34(24 males,10 females); mean age=50.4 years; baseline sitting SBP=151.6(15.9) mm Hg, DBP=102.1(5.6) mm Hg;
Placebo: n=31(21 males,10 females); mean age=48.2 years; baseline sitting SBP=150.7(14.3) mm Hg, DBP=101.7(4.9) mm Hg |
| Interventions |
Benazepril 5 mg once daily;
Benazepril 10 mg once daily;
Benazepril 20 mg once daily;
Benazepril 40 mg once daily;
Placebo |
| Outcomes |
Trough sitting DBP using mercury sphygmomanometer;
Mean change from baseline in peak sitting DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP reported, endpoint SE not reported; calculated SD of change from N and SE of change; DBP data from Table III, p. 325; Jadad score=2; funding source= Ciba‐Geigy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
